ulcerative colitis News
-
Lilly`s Mirikizumab Helps Patients Achieve Clinical Remission and Improves Symptoms in Adults with Ulcerative Colitis in 12-Week Phase 3 Induction Study
Eli Lilly and Company (NYSE: LLY) announced today that mirikizumab met the primary and all key secondary endpoints in LUCENT-1, a 12-week Phase 3 induction study evaluating the efficacy and safety of mirikizumab for the treatment of patients with moderate to severe ulcerative colitis (UC). LUCENT-2, a multicenter, randomized, double-blind, placebo-controlled maintenance study of mirikizumab in ...
-
ABC/13 women of distinction announced for 2011 winter ball
Eleven outstanding community volunteers have been named ABC/13 Women of Distinction and Ambassador for the 2011 Winter Ball, benefiting the Crohn's & Colitis Foundation of America (CCFA) Houston Gulf Coast/South Texas Chapter. An ABC/13 News photographer and a contingent of friends and admirers staged a series of surprise announcements at various Houston venues for the Women of Distinction ...
-
Microbiotica Receives Crohn’s & Colitis Foundation Funding to Develop Ulcerative Colitis Therapeutic
Microbiotica, a leading player in microbiome-based therapeutics and biomarkers, today announces it has received project funding from the Crohn’s & Colitis Foundation, as part of their IBD Ventures program, for the development of therapies to treat inflammatory bowel disease (IBD). The project, to support the ongoing development of Microbiotica’s Live Bacterial Therapeutic (LBT) ...
-
Microbiotica Highly Commended at Cambridge Independent Science and Technology Awards
Microbiotica, a leading player in microbiome-based therapeutics and biomarkers, has been highly commended in the “Life Science Company of the Year” category at the 4th Cambridge Independent Science and Technology Awards. The Company was recognised for its transformational technology and significant progress over the past year. Recent achievements include a key new strategic ...
-
Vedanta Biosciences Presents New Data from Phase 1 Study of VE202, Its Rationally-Defined Consortium for the Treatment of Inflammatory Bowel Disease, at the International Human Microbiome Consortium Congress 2021 (IHMC)
Results further support the benign safety profile of VE202 and identify an optimal dosing regimen Vedanta plans to initiate a Phase 2 clinical trial of VE202 in ulcerative colitis patients in the second half of 2021 Vedanta Biosciences, a leading clinical-stage microbiome company developing a new category of oral therapies using defined bacterial consortia manufactured from clonal cell ...
-
Microbiotica Announced as a Finalist in ‘Best Emerging Biotech Company’ Category at OBN Awards 2020
Microbiotica, a leading player in microbiome-based therapeutics and biomarkers, been selected as a finalist in the ‘Best Emerging Biotech Company’ category at the OBN Awards 2020. The winners will be announced on Thursday 26th November. Microbiotica has established itself as a leading global player in its field, and most recently it has been recognised for its collaboration with ...
-
Galapagos announces changes to Executive Committee
Dr. Walid Abi-Saab has decided to retire from the company as Chief Medical Officer and member of the Executive Committee, effective 31 December 2022. He will stay with Galapagos until 31 May 2023 to ensure a smooth transition. The company also announces the retirement of André Hoekema who joined Galapagos in 2005 as Chief Business Officer and member of the Executive Committee. Dr. Paul ...
By Galapagos NV
-
Microbiotica raises £50 million ($67 million) to advance pipeline of microbiome-based therapeutics
Microbiotica, a leading player in discovering and developing microbiome-based therapeutics and biomarkers, today announced the completion of a £50 million ($67 million) Series B financing round – the largest microbiome-related financing in Europe to date. The international investment syndicate was co-led by Flerie Invest, a major Swedish life science investor focussing on companies ...
-
CytoReason Announces Collaboration with Ferring to Identify Novel Therapeutic Targets in Inflammatory Bowel Disease Using AI Technology
TEL AVIV, Israel, May 19, 2021 /PRNewswire/ -- CytoReason, an Israeli company developing a computational model of the human body for faster drug discovery and development, today announced a collaboration with Swiss multinational biopharmaceutical company, Ferring Pharmaceuticals, which aims to establish new treatment options for patients with inflammatory bowel disease (IBD). This is the first ...
By CytoReason
-
Atmo Biosciences signs deal with RMIT University to commercialize ingestible gas-sensing capsule for gut health
Atmo Biosciences has signed a licensing deal with RMIT University securing the exclusive worldwide rights to commercialize a ground-breaking ingestible gas-sensing capsule. The Atmo Gas Capsule is set to revolutionize how doctors diagnose and treat common gastrointestinal (GI) disorders by offering a non-invasive, low-cost, and more accurate alternative to current technologies. Patients with ...
-
Microbiotica Wins Young Company of the Year at Business Weekly Awards
Microbiotica, a leading player in microbiome-based therapeutics and biomarkers, has been named Business Weekly Young Company of the Year 2020. The “Young Company of the Year” category is awarded to the most exciting recently incorporated enterprise in any sector that has made significant progress in the last 12 months. Microbiotica has been recognised for its continued development ...
-
Emory University research links functional thyroid disease, PFOA exposure
Excessive perfluorooctanoic acid (PFOA) exposure appears to be associated with thyroid disease, according to new research. A study by Kyle Steenland, environmental health professor at Emory University's Rollins School of Public Health, tracking the disease within a large high-exposure group concludes that the chemical “was associated with incident functional thyroid disease.” ...
-
NuMedii, Inc. Announces New Partnership To Discover and Advance New Treatments for Idiopathic Pulmonary Fibrosis
MENLO PARK, Calif., April 11, 2017 – NuMedii, Inc. today announced the formation of a strategic partnership with Three Lakes Partners, LLC, to discover and advance new treatments for idiopathic pulmonary fibrosis (IPF) based on NuMedii’s Big Data intelligence technology. Idiopathic pulmonary fibrosis is a rare chronic progressive and usually fatal interstitial lung disease for which ...
-
Alfa Chemistry Newly Introduces Three APIs to Meet Market Demands: Tofacitinib Citrate, Tamoxifen Citrate, and Epalrestat
Alfa Chemistry, a leading pharmaceutical supplier, has recently announced the addition of three new APIs to its full-ranged product catalog, i.e., tofacitinib citrate, tamoxifen citrate, and epalrestat. These new products are introduced to meet the growing demands of the pharmaceutical market. Tofacitinib Citrate Tofacitinib Citrate is a medication used to treat rheumatoid arthritis, psoriatic ...
-
Suono Bio, Inc. Announces Oversubscribed Series A Funding Round Led by Axil Capital and Mizuho Securities Principal Investment
Suono Bio, Inc., the company revolutionizing the treatment of gastrointestinal diseases, today announced it has raised an $8.5 million Series A financing led by Axil Capital and Mizuho Securities Principal Investment, with participation by Taiwania Capital and other investors. Suono Bio will utilize the funds to advance its lead programs in inflammatory bowel disease as well as expansion of its ...
By Suono Bio
-
Creative Proteomics Lipidomics Platform Boosts Short Chain Fatty Acids Research
Lipidomics, a platform developed by Creative Proteomics, is dedicated to providing cutting-edge mass spectrometry (MS)-based lipidomics services for biomedical research institutions, and biotechnological and pharmaceutical companies. The Lipidomics platform now employs gas chromatography-mass spectrometry (GC-MS) methods to enable fast and accurate qualitative and quantitative analysis of a ...
-
Second Genome Virtual KOL Event Highlighted Critical Role of Mucosal Healing and PAI-1/2 in Inflammatory Bowel Disease (IBD)
SG-5-00455, the Company’s development candidate for the treatment of IBD, aims to restore mucosal healing by targeting PAI-1/2 Second Genome, a biotechnology company that leverages its proprietary platform to discover and develop precision therapies and biomarkers, yesterday hosted a virtual key opinion leader (KOL) event focused on the role of mucosal healing and plasminogen activator ...
-
Galapagos announces CHMP adoption of PRAC’s recommendation for Jyseleca® following extensive safety review of all JAK inhibitors
Galapagos NV (Euronext & NASDAQ: GLPG) today announced that the Committee for Medicinal Products for Human Use (CHMP), the scientific committee of the European Medicines Agency (EMA), has adopted PRAC’s recommendation to add measures to minimise risk of serious side effects with JAK inhibitors for chronic inflammatory disorders. “JAK inhibitors are an important treatment option ...
By Galapagos NV
-
Galapagos announces strategy to accelerate innovation and reports strong third quarter 2022 results
Galapagos NV (Euronext & NASDAQ: GLPG) today announced its strategy for accelerated growth and value creation, its financial results for the first nine months of 2022, and the outlook for the remainder of 2022. The results are further detailed in the Q3 2022 financial report available on the financial reports section of the website. Forward, Faster strategy to accelerate innovation ...
By Galapagos NV
-
Fecal biomarkers - diagnostic possibilities in the context of inflammatory bowel disease
Inflammatory bowel disease (IBD), mainly divided into Crohn's disease (CD) and ulcerative colitis (UC), are diseases whose causes are not fully understood and for which there is no cure. The chronic progression of IBD is characterized by periods of symptomatic relapses and symptom-free phases. During relapses, acute inflammation occurs in the bowel of IBD patients, leading to typical symptoms ...
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you